British bank Barclays posted a sharp rise in second quarter profits Tuesday as traders benefited from volatility in global markets.Net profit jumped 36% to £2.3bn ($3.1bn) in the three months to the end of June, compared to one year earlier, Barclays said in an earnings statement. Chief executive CS Venkatakrishnan said the company "remain committed to, and confident in, delivering all financial and distribution targets for 2026 and 2028" — and announced a new £1bn share buyback.
Total income rose 16% to £8.3bn year-on-year. Its investment bank saw revenues jump 20% to nearly £4bn, "driven by global markets and investment banking fees". Sharp fluctuations in financial markets were exacerbated by big swings in oil prices linked to the Middle East war and on the twists and turns in the United States' trade policy, driving up volumes of financial transactions.
Revenue for Barclays' US consumer bank jumped 38% year on year.While the bank upgraded its group income target for 2026 — by £500mn — the figure fell short of expectations.The miss sent the company's share price sliding more than 5% on London's benchmark FTSE 100 index."The raising of the group projected income for the year to around £31.5bn from £31bn is perhaps typically conservative and brings a tinge of disappointment," said Richard Hunter, head of markets on Interactive Investor."For the most part, this is an unblemished release with strong growth across all areas of the group and spectacular progress in some," he added.
GSKBritish pharmaceutical giant GSK on Tuesday said it was targeting future annual savings of £1.9bn ($2.5bn) after bottom-line profits tumbled in the second quarter.Net profit in the second quarter slumped 70% to £435mn compared with the April-June period a year earlier after the company abandoned a chronic cough treatment, GSK said in an earnings statement. GSK said it had taken a hit totalling £1.3bn after not proceeding further with camlipixant following final stage trials.
The company announced earlier this month that the most recent tests showed "limited efficacy" and that the treatment was therefore "unlikely to transform patient care".GSK on Tuesday announced also the start of "a three-year cost savings programme to simplify the organisation and to reallocate capital and resources".
It added that a 2029 target had been set for the £1.9bn annual savings, without being drawn on possible job losses."We're not going to give a number today in terms of people changes," GSK chief executive Luke Miels told a call with media. "That's because I want the chance and I want my team to have the chance to discuss this with our people first." Stripping out the hit caused by camlipixant, GSK said its core operating profit rose 7% in the second quarter to £2.8 bn.Group revenue grew 5% to £8.4bn."GSK has delivered another quarter of strong core results performance, with our key growth drivers performing well," Miels said in the earnings release."We remain focused on operational delivery, execution, and accelerating" research and development (R&D).
UnileverUnilever on Tuesday upgraded its full-year outlook as it slims down and refocuses on its core home and personal care business.Profit after tax fell more than 5% to €3.3bn ($3.8bn) compared with the first half of 2025, said the maker of products including Dove soap and Cif surface cleaner.Unilever reported increases in both volume of sales and prices in the first half.
Under chief executive Fernando Fernandez, the company is undergoing a turnaround to boost its performance, including cutting jobs and spinning off its food and ice cream divisions.Fernandez highlighted a "strong volume-led performance in the first half, with a significant step-up in the second quarter." "The macroeconomic environment remains uncertain, but... we are well positioned to deliver our upgraded full year outlook," he said in an earnings statement.Higher inflation, triggered by a surge in energy costs linked to the Middle East war, has weighed on consumer confidence, dampening the outlook for spending.
The group now expects underlying sales growth of between four to six % this year, having previously forecast growth at the bottom end of that range.Mercedes-BenzPremium German carmaker Mercedes-Benz on Tuesday reported falling profit at its car business as it wrote off over €700mn due to fierce competition in China.
Though overall net profit for the quarter rose 13.5% to €1.09bn ($1.24bn), boosted by its vans and financial services businesses, core earnings at the key cars division fell 26% to €909mn, Mercedes said, hit by competition in China.
The figure does not include a non-cash write-down of €704mn Mercedes booked in the value of its Chinese investments, indicating it sees lasting trouble ahead in the world's largest car market.Including the write-down, profit at Mercedes-Benz's car business plummeted almost 94%."The Chinese market and customers in China remain of high strategic importance to Mercedes-Benz," the firm said in a statement."Intense competition, subdued demand and the portfolio-wide model changeover continued to affect sales," it added.Premium German carmakers have not been spared the cutthroat Chinese competition that has also hit volume manufacturer Volkswagen.Porsche on Monday said another 5,000 jobs would go by 2035, bringing total announced job cuts to 9,000, and BMW last month said it would prepare cost-cutting measures after slashing its core profit margin forecast for the year to as low as one 1%.
LVMHLVMH, the world's top luxury group, said on Monday that sales growth accelerated in the second quarter as it beat analyst expectations with stable net profit in the first half of the year.
The performance of the group, whose brands include Louis Vuitton, Dior, Celine and Hennessy, could be a sign that the struggling luxury sector is starting to turn the corner.LVMH said it posted a net profit of €5.7bn ($6.5bn) despite the "geopolitical and economic environment that remained disrupted, amplified by the conflict in the Middle East".First-half sales dipped by 3% to €38.6bn. Both figures beat the consensus of analyst expectations compiled by FactSet.
While the group's sales slumped 6% in the first three months of the year, they edged 0.1 % higher in the second quarter to €19.5bn.AstraZenecaBritish pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs.
Profit after tax climbed more than 2% to $2.5bn in the three months to the end of June, compared with the same period last year, AstraZeneca said in a results statement.Group revenue increased 6% to $15.4bn in the quarter, thanks to sustained strong demand for its cancer and rare disease medicines.AstraZeneca reconfirmed its outlook for the full year after its latest profit beat analyst expectations.
Chief executive Pascal Soriot said the company was "on track" to deliver its ambition of $80bn in total revenue by 2030, despite an unexpected late-stage trial failure earlier this month.
